Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben Tran

Showing results (91-100 of 170) with videos related to

Pageof 17
Sort By:
Asia-Pacific Journal of Clinical Oncology|September 24, 2020
Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive diseaseAndrew Schmidt, Angelyn Anton, Julia Shapiro, et al.
BJUI Compass|May 2, 2022
Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancerAngelyn Anton, Sruti Pillai, Marie Christine Semira, et al.
Clinical & Translational Immunology|September 21, 2020
CD8<sup>+</sup> tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous <i>de novo</i> metastatic colorectal carcinoma do not track with survivalRosemary Millen, Shona Hendry, Vignesh Narasimhan, et al.
JNCI Cancer Spectrum|April 28, 2020
Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic IndexDaphne Day, Christina Guo, Yada Kanjanapan, et al.
European Urology Open Science|October 3, 2022
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell CarcinomaCristian Udovicich, Jason Callahan, Mathias Bressel, et al.
British Journal of Cancer|May 26, 2023
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumorsAnthony B El-Khoueiry, James Clarke, Tobias Neff, et al.
Asia-Pacific Journal of Clinical Oncology|March 17, 2017
How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia?Lewis Au, Natalie Turner, Hui-Li Wong, et al.
BJU International|October 8, 2021
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancerRichard Kelly, Angelyn Anton, Shirley Wong, et al.
Genomics|April 23, 2013
Clinical genomics information management software linking cancer genome sequence and clinical decisionsStuart Watt, Wei Jiao, Andrew M K Brown, et al.
European Urology Oncology|October 8, 2023
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)Andrew Weickhardt, Farshad Foroudi, Nathan Lawrentschuk, et al.
Pageof 17

Showing results (91-100 of 170) with videos related to

Sort By:
Pageof 17
Asia-Pacific Journal of Clinical Oncology|September 24, 2020
Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive diseaseAndrew Schmidt, Angelyn Anton, Julia Shapiro, et al.
BJUI Compass|May 2, 2022
Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancerAngelyn Anton, Sruti Pillai, Marie Christine Semira, et al.
Clinical & Translational Immunology|September 21, 2020
CD8<sup>+</sup> tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous <i>de novo</i> metastatic colorectal carcinoma do not track with survivalRosemary Millen, Shona Hendry, Vignesh Narasimhan, et al.
JNCI Cancer Spectrum|April 28, 2020
Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic IndexDaphne Day, Christina Guo, Yada Kanjanapan, et al.
European Urology Open Science|October 3, 2022
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell CarcinomaCristian Udovicich, Jason Callahan, Mathias Bressel, et al.
British Journal of Cancer|May 26, 2023
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumorsAnthony B El-Khoueiry, James Clarke, Tobias Neff, et al.
Asia-Pacific Journal of Clinical Oncology|March 17, 2017
How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia?Lewis Au, Natalie Turner, Hui-Li Wong, et al.
BJU International|October 8, 2021
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancerRichard Kelly, Angelyn Anton, Shirley Wong, et al.
Genomics|April 23, 2013
Clinical genomics information management software linking cancer genome sequence and clinical decisionsStuart Watt, Wei Jiao, Andrew M K Brown, et al.
European Urology Oncology|October 8, 2023
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)Andrew Weickhardt, Farshad Foroudi, Nathan Lawrentschuk, et al.
Pageof 17